150 related articles for article (PubMed ID: 20683398)
1. Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels.
Richard SD; Sukumvanich P; Lesnock JL; McBee WC; Beriwal S; Edwards RP; Zorn KK; Krivak TC
Int J Gynecol Cancer; 2010 Aug; 20(6):932-5. PubMed ID: 20683398
[TBL] [Abstract][Full Text] [Related]
2. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.
Richardson DL; Seamon LG; Carlson MJ; O'Malley DM; Fowler JM; Copeland LJ; Cohn DE
Gynecol Oncol; 2008 Nov; 111(2):233-6. PubMed ID: 18768214
[TBL] [Abstract][Full Text] [Related]
3. CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.
Gardner GJ; Baser RE; Brady MF; Bristow RE; Markman M; Spriggs D; Thaler HT
Gynecol Oncol; 2012 Feb; 124(2):216-20. PubMed ID: 22033034
[TBL] [Abstract][Full Text] [Related]
4. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
5. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
6. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS
J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
[TBL] [Abstract][Full Text] [Related]
9. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.
Krivak TC; Tian C; Rose GS; Armstrong DK; Maxwell GL
Gynecol Oncol; 2009 Oct; 115(1):81-85. PubMed ID: 19596139
[TBL] [Abstract][Full Text] [Related]
10. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
Fujiwara K; Sakuragi N; Suzuki S; Yoshida N; Maehata K; Nishiya M; Koshida T; Sawai H; Aotani E; Kohno I
Gynecol Oncol; 2003 Sep; 90(3):637-43. PubMed ID: 13678738
[TBL] [Abstract][Full Text] [Related]
11. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
Oaknin A; Roda D; González-Martín A; Chiva L; García-Donas J; de Juan A; Redondo A; Martínez S; García Y; Catot S; Ponce J; Del Campo JM; Cervantes A; Poveda A
Int J Gynecol Cancer; 2011 Aug; 21(6):1048-55. PubMed ID: 21738038
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
[TBL] [Abstract][Full Text] [Related]
15. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
[TBL] [Abstract][Full Text] [Related]
16. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
18. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
Bruixola G; Domingo S; Díaz R; Caballero J; Palomar L; De La Cueva H; Santaballa A
Int J Gynecol Cancer; 2015 Feb; 25(2):214-21. PubMed ID: 25415075
[TBL] [Abstract][Full Text] [Related]
20. The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer.
Tsuda H; Hashiguchi Y; Nakata S; Deguchi M; Negoro S; Ishiko O; Yamamoto K
Int J Gynecol Cancer; 2002; 12(5):435-7. PubMed ID: 12366658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
